Medication info
Nesina Act Tablets 25/30 mg (Alogliptin Benzoate, Pioglitazone Hydrochloride)

Nesina Act Tablets 25/30 mg (Alogliptin Benzoate, Pioglitazone Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Alogliptin Benzoate›34mg / 1 tabletPioglitazone Hydrochloride›33.06mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
Pink, round, biconvex film-coated tablets
Packaging
28 tablets/Alu-Alu[(14TX2ea)], 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202303456 · Approved 2023.12.28 · Insurance code 693903860

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This medicine is administered once daily, regardless of meals. Do not split the tablets. The recommended starting dose of this medicine (alogliptin/pioglitazone) is as follows. ● For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy: Administer this medicine 25mg/15mg. ● For patients who cannot achieve adequate glycemic control with metformin monotherapy: Administer this medicine 25mg/15mg. ● For patients who cannot achieve adequate glycemic control with pioglitazone monotherapy: Administer this medicine 25mg/15mg or 25mg/30mg, depending on the current treatment regimen. ● For patients who cannot achieve adequate glycemic control with combination therapy of pioglitazone and metformin: Administer this medicine 25mg/15mg or 25mg/30mg, depending on the current treatment regimen. ● Substitution for combination therapy with alogliptin and pioglitazone: When switching from combination therapy with alogliptin and pioglitazone to this medicine, start with the current doses of alogliptin and pioglitazone. The dose of this medicine may be increased to a maximum of 25mg/30mg once daily, depending on the glycemic response. When starting treatment with this medicine or increasing the dose, carefully monitor patients for adverse reactions associated with fluid retention observed with pioglitazone treatment (e.g., weight gain, edema, and signs and symptoms of congestive heart failure). Patients with renal impairment - Patients with mild renal impairment (creatinine clearance ≥50 mL/min): No dose adjustment is necessary. - Patients with moderate renal impairment (creatinine clearance ≥30~ <50 mL/min): Administer this medicine 12.5 mg/15 mg or 12.5 mg/30 mg once daily. - This medicine should not be administered to patients with severe renal impairment or end-stage renal disease. - Because dose adjustment may be necessary depending on renal function, assessment of renal function is recommended before starting treatment with this medicine and periodically thereafter.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

View approved original text

This medication is used to assist blood sugar control in patients with type 2 diabetes. It is effective when taken alongside dietary regulation and exercise therapy, helping to manage blood sugar more stably through the combination of alogliptin and pioglitazone. This medicine improves patients' blood sugar levels and aids in diabetes management.

Dosage and Administration

Adult dosage

This medicine is administered once daily, regardless of meals. Do not split the tablets. The recommended starting dose of this medicine (alogliptin/pioglitazone) is as follows. ● For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy: Administer this medicine 25mg/15mg. ● For patients who cannot achieve adequate glycemic control with metformin monotherapy: Administer this medicine 25mg/15mg. ● For patients who cannot achieve adequate glycemic control with pioglitazone monotherapy: Administer this medicine 25mg/15mg or 25mg/30mg, depending on the current treatment regimen. ● For patients who cannot achieve adequate glycemic control with combination therapy of pioglitazone and metformin: Administer this medicine 25mg/15mg or 25mg/30mg, depending on the current treatment regimen. ● Substitution for combination therapy with alogliptin and pioglitazone: When switching from combination therapy with alogliptin and pioglitazone to this medicine, start with the current doses of alogliptin and pioglitazone. The dose of this medicine may be increased to a maximum of 25mg/30mg once daily, depending on the glycemic response. When starting treatment with this medicine or increasing the dose, carefully monitor patients for adverse reactions associated with fluid retention observed with pioglitazone treatment (e.g., weight gain, edema, and signs and symptoms of congestive heart failure). Patients with renal impairment - Patients with mild renal impairment (creatinine clearance ≥50 mL/min): No dose adjustment is necessary. - Patients with moderate renal impairment (creatinine clearance ≥30~ <50 mL/min): Administer this medicine 12.5 mg/15 mg or 12.5 mg/30 mg once daily. - This medicine should not be administered to patients with severe renal impairment or end-stage renal disease. - Because dose adjustment may be necessary depending on renal function, assessment of renal function is recommended before starting treatment with this medicine and periodically thereafter.

Precautions

This medication is used for the treatment of type 2 diabetes, helping to control blood sugar. Due to the presence of pioglitazone, it may worsen symptoms of heart failure; therefore, patients with heart failure should not use this medication. While taking this medication, weight gain or edema may occur, and if symptoms of heart failure appear, medical personnel should be informed immediately. Patients with a history of bladder cancer or those currently diagnosed with bladder cancer should not use this medication, and if visible hematuria or urination troubles occur, they should consult a doctor promptly. Women who are pregnant or may become pregnant, as well as breastfeeding women, should avoid taking this medication. Patients with severely impaired kidney or liver function, those with severe infections or before and after surgery, and patients with type 1 diabetes should not use this medication. This medication poses a risk of hypoglycemia when combined with other diabetes medications; therefore, dosage adjustments may be necessary when taking insulin or sulfonylureas. Additionally, if any unusual symptoms such as pancreatitis, severe hypersensitivity reactions, liver function abnormalities, macular edema, or severe arthralgia occur while taking this medication, inform medical personnel immediately. Elderly patients, premenopausal women, patients with edema, and those with poor nutritional status should use this medication cautiously with regular monitoring. This medication generally exhibits fewer interactions with other drugs, but dosage adjustments may be necessary when used in combination with specific medications; therefore, all medications being taken should be reported to medical personnel. Finally, this medication should be stored out of reach of children and kept in its original container for safety.

Side effects

Congestive heart failure, excessive and rapid weight change, dyspnea, edema, fluid retention, worsening of congestive heart failure, severe heart failure, visible hematuria, urinary disorders, urgency, nasopharyngitis, back pain, upper respiratory infection, influenza, hypoglycemia, headache, pancreatitis, hypersensitivity reaction, serum sickness, sinusitis, myalgia, pharyngitis, weight gain, hepatotoxicity, elevated serum ALT levels, increased creatine kinase, vision impairment, diabetic macular edema, fatal liver failure, non-fatal liver failure, bladder cancer, hematological changes, decreased hemoglobin, decreased hematocrit, musculoskeletal disorders, tendinitis, fractures, costochondritis, leg fractures, upper limb fractures, spinal fractures, rhabdomyolysis, thyroid carcinoma, lung cancer, pulmonary carcinoma, acute pancreatitis, diarrhea, gastric ulcer, exacerbation of gastritis, hemorrhagic gastric ulcer, appendicitis, hematological abnormalities, dyspnea, exacerbation of asthma, worsening pneumonia, respiratory arrest, abscess, infection, wound dehiscence, chest discomfort, generalized edema, general weakness, cirrhosis, cholelithiasis, acute renal failure, kidney stones, renal dysfunction, myocardial infarction, angina, loss of appetite, cerebral infarction, transient ischemic attack, exacerbation of atrial fibrillation, speech disturbance, platelet abnormalities, bleeding, coagulation disorders, contusion, loss of appetite, depression, hypersensitivity, erectile dysfunction, insomnia, sleep disorders, benign prostatic hyperplasia, benign prostatic hypertrophy, orthostatic hypotension, hypotension, tinnitus, acute hearing loss, Meniere's disease, coronary occlusion, exacerbation of angina, bradycardia, palpitations, itching, hematuria, conjunctivitis, glaucoma, macular degeneration, cataract, corneal inflammation, retinal disease, retinal disorders, retinal pathologies, diabetic retinopathy, cholelithiasis, unexplained liver function test abnormalities, cirrhosis, biliary sclerosis, fatty liver, increased AST, increased ALT, shingles, herpes labialis, herpes virus infection, insomnia, itching, onychomycosis, pyelonephritis, ureteral stones, stomatitis, abdominal pain, gastroesophageal reflux, gastroesophageal reflux disease, gastrointestinal disturbances, atrophic gastritis, pain unrelated to food in the epigastric region, enteritis, heartburn, constipation, gastric intestinal air retention, gastritis, vomiting, cough, phlegm disorders, bronchitis, rhinitis, pharyngitis, chest pain, lower back pain, hyperglycemia, hyperlipidemia, diabetes complications, dyslipidemia, increased triglycerides, dizziness, lightheadedness, cerebral disorders, arthralgia, neck/shoulder pain, arthrosis, leg weakness, malaise, fever, fatigue, pain, buttock pain, chest pain exacerbation, tendon rupture, leg fractures, shingles, hypertension, insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is advisable to maintain the storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, round, biconvex film-coated tablets

Package unit

28 tablets/Alu-Alu[(14TX2ea)], 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.